Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.52 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NMT1 | P30419 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12015830 | 0.88 | SIGMAR1 (0.68) | SIGMAR1MBTD1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL12015826 | 0.86 | SIGMAR1 (0.55) | SIGMAR1MBTD1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL12015827 | 0.84 | PKM (0.65) | SIGMAR1ALDH1A1PKMMAPK1KMT2A | |
| SCHEMBL9152088 | 0.84 | L3MBTL1 (0.63) | SIGMAR1MBTD1L3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL29172771 | 0.82 | HTR7 (0.60) | SIGMAR1ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL6291984 | 0.80 | SIGMAR1 (0.52) | SIGMAR1MBTD1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL12015817 | 0.80 | LOX (0.53) | ALDH1A1GAAMAPK1HTR6NMT1 | |
| SCHEMBL14132491 | 0.79 | L3MBTL1 (0.71) | SIGMAR1MBTD1L3MBTL1KMT2A | |
| SCHEMBL9895010 | 0.78 | HTR7 (0.65) | ALDH1A1PKMHTR6 | |
| SCHEMBL12074406 | 0.77 | MBTD1 (0.78) | MBTD1L3MBTL1ALDH1A1ALOX15NMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130243754-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8372971-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120220584-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8084618-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220584-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | SIGMAR1 2151/4885MBTD1 2247/4885L3MBTL1 3616/4885 |
| US-20130243754-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | SIGMAR1 2151/4885MBTD1 2247/4885L3MBTL1 3616/4885 |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | SIGMAR1 2151/4885MBTD1 2247/4885L3MBTL1 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.